1,427 reports of this reaction
4.0% of all PIPERACILLIN SODIUM AND TAZOBACTAM SODIUM reports
#2 most reported adverse reaction
PYREXIA is the #2 most commonly reported adverse reaction for PIPERACILLIN SODIUM AND TAZOBACTAM SODIUM, manufactured by Fresenius Kabi USA, LLC. There are 1,427 FDA adverse event reports linking PIPERACILLIN SODIUM AND TAZOBACTAM SODIUM to PYREXIA. This represents approximately 4.0% of all 35,839 adverse event reports for this drug.
Patients taking PIPERACILLIN SODIUM AND TAZOBACTAM SODIUM who experience pyrexia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
PYREXIA is moderately reported among PIPERACILLIN SODIUM AND TAZOBACTAM SODIUM users, representing a notable but not dominant share of adverse events.
In addition to pyrexia, the following adverse reactions have been reported for PIPERACILLIN SODIUM AND TAZOBACTAM SODIUM:
The following drugs have also been linked to pyrexia in FDA adverse event reports:
PYREXIA has been reported as an adverse event in 1,427 FDA reports for PIPERACILLIN SODIUM AND TAZOBACTAM SODIUM. This does not prove causation, but indicates an association observed in post-market surveillance data.
PYREXIA accounts for approximately 4.0% of all adverse event reports for PIPERACILLIN SODIUM AND TAZOBACTAM SODIUM, making it one of the most commonly reported side effect.
If you experience pyrexia while taking PIPERACILLIN SODIUM AND TAZOBACTAM SODIUM, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.